Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model

Even when treated with aggressive current therapies, most patients with glioblastoma survive less than two years. Rapid tumor growth, an invasive nature, and the blood-brain barrier, which limits the penetration of large molecules into the brain, all contribute to the poor tumor response associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouyang, Mao, White, Ethan E., Ren, Hui, Guo, Qin, Zhang, Ian, Gao, Hang, Yanyan, Song, Chen, Xuebo, Weng, Yiming, Da Fonseca, Anna, Shah, Sunny, Manuel, Edwin R., Zhang, Leying, Vonderfecht, Steven L., Alizadeh, Darya, Berlin, Jacob M., Badie, Behnam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734656/
https://www.ncbi.nlm.nih.gov/pubmed/26829221
http://dx.doi.org/10.1371/journal.pone.0148139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734656/
https://www.ncbi.nlm.nih.gov/pubmed/26829221
http://dx.doi.org/10.1371/journal.pone.0148139

Ejemplares similares